Targagenix, Inc.
STONY BROOK, United States · Founded 2015
- Headquarters
- STONY BROOK, New York
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
About
TargaGenix, Inc. is a Stony Brook University spinout developing novel cancer therapies that target both cancer stem cells and bulk tumor cells. Its lead compound DHA-SBT-1214 (NE-DHA-SBT-1214) originated from a 10+ year discovery effort by Distinguished Professor Iwao Ojima and has shown preclinical efficacy against chemotherapy-resistant solid tumors, particularly colorectal cancer. The technology was licensed from Stony Brook University in 2016.
Summary
Targagenix, Inc. is a Biotech company based in STONY BROOK, United States, founded in 2015.
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/targagenix-inc"><img src="https://indexed.vc/api/badge/company/targagenix-inc" alt="Targagenix, Inc. on Indexed.vc" width="260" height="76" /></a>